These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38196286)

  • 61. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
    Parodi G; Marcucci R; Valenti R; Gori AM; Migliorini A; Giusti B; Buonamici P; Gensini GF; Abbate R; Antoniucci D
    JAMA; 2011 Sep; 306(11):1215-23. PubMed ID: 21934054
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial.
    Verdoia M; Suryapranata H; Damen S; Camaro C; Benit E; Barbieri L; Rasoul S; Liew HB; Polad J; Ahmad WAW; Zambahari R; Lalmand J; van der Schaaf RJ; Koh TH; Timmermans P; Dilling-Boer D; Veenstra LF; Van't Hof AWJ; Lee SWL; Roolvink V; Ligtenberg E; Postma S; Kolkman EJJ; Brouwer MA; Kedhi E; De Luca G
    J Thromb Thrombolysis; 2021 Oct; 52(3):797-807. PubMed ID: 33847862
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic implications of stress hyperglycemia ratio in patients with myocardial infarction with nonobstructive coronary arteries.
    Gao S; Huang S; Lin X; Xu L; Yu M
    Ann Med; 2023 Dec; 55(1):990-999. PubMed ID: 36896774
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study.
    Valenti R; Marcucci R; Capodanno D; De Luca G; Migliorini A; Gori AM; Parodi G; Giusti B; Carrabba N; Paniccia R; Cantini G; Marrani M; Gensini GF; Abbate R; Antoniucci D
    J Thromb Thrombolysis; 2015 Jul; 40(1):76-82. PubMed ID: 25502874
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of immature platelets with perioperative complications in neurosurgery.
    Anetsberger A; Bernlochner I; Jungwirth B; Blobner M; Meyer B; Kochs EF; Bongiovanni D; Schmid S; Langgartner C; Baumgart L; Gempt J
    Platelets; 2023 Dec; 34(1):2185462. PubMed ID: 36974887
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry.
    Ge Z; Baber U; Claessen BE; Farhan S; Chandrasekhar J; Li SX; Sartori S; Kini AS; Rao SV; Weiss S; Henry TD; Vogel B; Sorrentino S; Faggioni M; Kapadia S; Muhlestein B; Strauss C; Toma C; DeFranco A; Effron MB; Keller S; Baker BA; Pocock S; Dangas G; Mehran R
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):E112-E119. PubMed ID: 30351514
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of Midterm Outcomes Associated With Aspirin and Ticagrelor vs Aspirin Monotherapy After Coronary Artery Bypass Grafting for Acute Coronary Syndrome.
    Björklund E; Malm CJ; Nielsen SJ; Hansson EC; Tygesen H; Romlin BS; Martinsson A; Omerovic E; Pivodic A; Jeppsson A
    JAMA Netw Open; 2021 Aug; 4(8):e2122597. PubMed ID: 34436610
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
    You J; Li H; Guo W; Li J; Gao L; Wang Y; Geng L; Wang X; Wan Q; Zhang Q
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():598-605. PubMed ID: 31957972
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety of Clopidogrel vs. Ticagrelor in Dual Antiplatelet Therapy Regimens for High-Bleeding Risk Acute Coronary Syndrome Patients: A Comprehensive Meta-analysis of Adverse Outcomes.
    Khalid AR; Ahmad F; Naeem MAB; Ahmed S; Umar M; Mehmood H; Kashif M; Ali S
    High Blood Press Cardiovasc Prev; 2024 Mar; 31(2):141-155. PubMed ID: 38557855
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
    Hagström E; Roe MT; Hafley G; Neely ML; Sidhu MS; Winters KJ; Prabhakaran D; White HD; Armstrong PW; Fox KA; Ohman EM; Boden WE;
    Clin Cardiol; 2016 Jun; 39(6):329-37. PubMed ID: 27177240
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
    Marcucci R; Giusti B; Paniccia R; Gori AM; Saracini C; Valente S; Giglioli C; Parodi G; Antoniucci D; Gensini GF; Abbate R
    Platelets; 2012; 23(8):586-93. PubMed ID: 22390861
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention.
    Faggioni M; Baber U; Chandrasekhar J; Sartori S; Claessen BE; Rao SV; Vogel B; Effron MB; Poddar K; Farhan S; Kini A; Weintraub W; Toma C; Sorrentino S; Weiss S; Snyder C; Muhlestein JB; Kapadia S; Keller S; Strauss C; Aquino M; Baker B; Defranco A; Pocock S; Henry T; Mehran R
    Int J Cardiol; 2019 Jan; 275():31-35. PubMed ID: 30391067
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Laine M; Panagides V; Frère C; Cuisset T; Gouarne C; Jouve B; Thuny F; Paganelli F; Alessi MC; Mancini J; Bonello L
    J Thromb Haemost; 2019 Dec; 17(12):2188-2195. PubMed ID: 31351022
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Risk scoring to guide antiplatelet therapy post-percutaneous coronary intervention for acute coronary syndrome results in improved clinical outcomes.
    Antoniou S; Colicchia M; Guttmann OP; Rathod KS; Wright P; Fhadil S; Knight CJ; Jain AK; Smith EJ; Mathur A; Weerackody R; Wragg A; Jones DA
    Eur Heart J Qual Care Clin Outcomes; 2018 Oct; 4(4):283-289. PubMed ID: 29126112
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization.
    Marquis-Gravel G; Neely ML; Valgimigli M; Costa F; Van Klaveren D; Altner R; Bhatt DL; Armstrong PW; Fox KAA; White HD; Ohman EM; Roe MT
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006582. PubMed ID: 32862694
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry.
    Cerrato E; Giacobbe F; Quadri G; Macaya F; Bianco M; Mori R; Biolè CA; Boi A; Bettari L; Rolfo C; Ferrari F; Annibali G; Scappaticci M; Pavani M; Barbero U; Buccheri D; Cavallino C; Lombardi P; Bernelli C; D'Ascenzo F; Infantino V; Gambino A; Cinconze S; Rognoni A; Montagna L; Porto I; Musumeci G; Escaned J; Varbella F;
    Eur Heart J; 2021 Aug; 42(33):3161-3171. PubMed ID: 34338759
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Contemporary Antiplatelet Treatment in Acute Coronary Syndrome Patients with Impaired Renal Function Undergoing Percutaneous Coronary Intervention.
    Davlouros P; Xanthopoulou I; Goudevenos J; Hamilos M; Vavuranakis E; Sitafidis G; Kanakakis I; Deftereos S; Alexopoulos D
    Cardiology; 2017; 138(3):186-194. PubMed ID: 28750372
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
    Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
    J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.